Celltrion's Zymfentra prescriptions in the US reached record highs in January 2026, surging 213% year-on-year, with shipments to distributors increasing 3.5-fold, driven by the company's comprehensive 3P marketing strategy targeting providers, payers, and patients across multiple channels.
#YonhapInfomax #Celltrion #Zymfentra #Infliximab #PrescriptionGrowth #USPharmaceuticalMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=110507

💊💉 #infliximab SmPC for Remicade® 100 mg powder for concentrate for solution for infusion. has been updated with changes to sections 4.4 Special warnings; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.6 Special precautions for disposal; Revised: 20/12/2023. 🌐 https://www.medicines.org.uk/emc/product/3831/smpc Change log: https://www.medicines.org.uk/emc/product/3831/smpc/history

💊💉 #infliximab
SmPC for Remsima 120 mg solution for injection in pre-filled pen has been updated with changes to sections 4.8 Undesirable effects; 10. Date of revision of the text on 09/09/2024.
🌐 https://www.medicines.org.uk/emc/product/11101/smpc
Change log: https://www.medicines.org.uk/emc/product/11101/smpc/history

💊💉 #infliximab
SmPC for Remsima 100 mg powder for concentrate for solution for infusion has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 9. Date of first authorisation/renewal of the authorisation; 10. Date of revision of the text on 09/09/2024.
🌐 https://www.medicines.org.uk/emc/product/3709/smpc
Change log: https://www.medicines.org.uk/emc/product/3709/smpc/history

💊💉 #infliximab SmPC for Remsima 120 mg solution for injection in pre-filled pen has been updated with changes to sections 2. Qualitative; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 6.4 Special precautions for storage; 6.5 Nature; Revised: 26/07/2024. 🌐 https://www.medicines.org.uk/emc/product/11101/smpc Change log: https://www.medicines.org.uk/emc/product/11101/smpc/history

💊💉 #infliximab SmPC for Flixabi 100 mg powder for concentrate for solution for infusion has been updated with changes to sections 4.2 Posology; 4.4 Special warnings; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.3 Preclinical safety data; 6.3 Shelf life; 6.4 Special precautions for storage; 6.6 Special precautions for disposal; Revised: 05/07/2024. 🌐 https://www.medicines.org.uk/emc/product/7265/smpc Change log: https://www.medicines.org.uk/emc/pro ...

💊💉 #infliximab SmPC for Remsima 100 mg powder for concentrate for solution for infusion has been updated with changes to sections 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; Revised: 12/12/2023. 🌐 https://www.medicines.org.uk/emc/product/3709/smpc Change log: https://www.medicines.org.uk/emc/product/3709/smpc/history

💊💉 #infliximab SmPC for Remsima 120 mg solution for injection in pre-filled pen has been updated with changes to sections 2. Qualitative; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 6.3 Shelf life; 6.5 Nature; Revised: 12/12/2023. 🌐 https://www.medicines.org.uk/emc/product/11101/smpc Change log: https://www.medicines.org.uk/emc/product/11101/smpc/history